Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function
NCT01923870
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class
Conditions
Secondary Hypogonadism
Interventions
DRUG:
Androxal 25 mg
Sponsor
Repros Therapeutics Inc.